Valneva begins phase III COVID-19 vaccine trial

By The Science Advisory Board staff writers

April 22, 2021 -- Valneva announced it has initiated a phase III trial to evaluate its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The company's Cov-Compare trial will pit VLA2001 against AstraZeneca's conditionally approved vaccine, Vaxzevria, in a comparative immunogenicity trial.

The U.K. trial will enroll 4,000 participants who will receive two doses of either vaccine. The primary end point of Cov-Compare will be to determine immune response two weeks after completion of a two-dose immunization schedule administered in a four-week interval.

Pending results, Valneva plans to submit the vaccine for initial approval later this year, the company stated.

Valneva posts positive early clinical data for adjuvanted COVID-19 vaccine
Valneva is directing attention to positive results from the phase I/II clinical trial of its VLA2001, an inactivated, adjuvanted COVID-19 vaccine candidate.
Clinical pipeline promises effective 2nd-generation COVID-19 vaccines
Despite the small number of COVID-19 vaccines that have been granted emergency use authorizations by the U.S. Food and Drug Administration to date, many...
Dynavax helps advance COVID-19 vaccine candidates
Dynavax Technologies said it will be providing additional quantities of its CpG 1018 adjuvant for Valneva's SARS-CoV-2 vaccine candidate and has also...
Valneva begins COVID-19 vaccine production
Valneva has begun production of its inactivated COVID-19 vaccine candidate in conjunction with ongoing clinical studies from which the company expects...
Valneva begins clinical trials for inactivated, adjuvanted COVID-19 vaccine
Valneva has begun a phase I/II clinical trial to study its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

Copyright © 2021

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter